Fendy Yanhui Feng – President, Eisai China
Fendy Yanhui Feng, vice president of Eisai Co., Ltd. and president of Eisai China Holdings Ltd. and Eisai China Inc., shares the significant improvements she has made to Eisai’s China…
Eisai China has grown steadily since it entered the Chinese market in the early 1990s. Since 1991, Shenyang Weiya Pharmaceutical Co., Ltd. and Eisai (Suzhou) Pharmaceutical Co., Ltd. have been established. In 2002, it was officially renamed as Eisai (China) Pharmaceutical Co., Ltd. With the development of China’s business, Eisai (Suzhou) Trading Co., Ltd. was established in 2010, and Eisai (China) Investment Co., Ltd. was established in 2014. In 2015, the company officially established Eisai through the acquisition of a local generic drug company. Liaoning) Pharmaceutical Co., Ltd. So far, the company has established the management of Eisai (China) Investment Co., Ltd., and is supported by Eisai (China) Pharmaceutical Co., Ltd., Eisai (Liaoning) Pharmaceutical Co., Ltd. and Eisai (Suzhou) Trading Co., Ltd. Development model. In order to adapt to the rapid development of China’s business, in November 2014, the Injectables Factory of Eisai (China) Pharmaceutical Co., Ltd. was completed. In November 2017, the new solid preparation plant was completed, and the production capacity of Eisai China was hugely increased.
Contact
Address: 39th-40th Floor, Park Place, No.1601, Nanjing Xi Road, Shanghai City, 200040 China
Tel: +86 21 24192888
Website: http://www.eisai.com.cn/
Fendy Yanhui Feng, vice president of Eisai Co., Ltd. and president of Eisai China Holdings Ltd. and Eisai China Inc., shares the significant improvements she has made to Eisai’s China…
Former director general of the Chinese Center for Disease Control and Prevention (CDC) and current chairman of the Chinese Foundation for Hepatitis Prevention and Control, Professor Yu Wang, weighs in…
After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune…
Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been…
Jimmy Wei founded Chime Biologics over 12 years ago with the vision of establishing a global biologics company in China, focusing on biosimilar development and CDMO services. The company’s growth…
Boan Biotech CEO Jiang Hua outlines the Luye Pharma-acquired company’s approach, securing stable revenues through its biosimilars while pursuing novel platforms and innovative drug development. She provides insights into the…
BeiGene may not be a profitable business quite yet, but the Chinese biotech has two top oncology products and saw its sales soar to USD 2.2 billion in 2023. Having…
Cytiva is a global leader in bioprocessing technologies and services that support the manufacturing and research of biopharmaceuticals. China is a key market in the company’s growth story, where –…
Unlike many of its Chinese biotech peers with broad portfolios, Hua Medicine has focused intensively on developing a single product, dorzagliatin, for diabetes. As CEO Li Chen notes, this strategic…
Yoshitaka Koketsu explains Sumitomo Pharma Group’s positioning in the China market as a relatively recent market entrant with a six-product portfolio but with plentiful opportunities for further growth, particularly in…
Global pharma has been stepping up M&A activity in Asia while also looking to access Asian markets through local partners and tap into the region’s huge growth potential. As a…
HKEX-main board listed Alphamab Oncology is one of China’s leading biotech success stories, having developed and marketed the world’s first subcutaneously injectable PD-L1 inhibitor. Founder, Chairman, and CEO Dr Xu…
Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA…
See our Cookie Privacy Policy Here
